William DeVaul Email

General Counsel, Corporate Secretary and Chief Compliance Officer . Morphic Therapeutic

Current Roles

Employees:
131
Revenue:
$26.3M
About
Oral integrin therapies for patients with immunological, fibrotic, neoplastic and vascular diseases. Morphic Tx is joining a three decade quest led by our scientific founder, Tim Springer, who initially discovered the integrin receptor family in the 1980s. This receptor family is an important drug target that has fueled the successful development of six injectable therapies approved for treatment of multiple sclerosis, ulcerative colitis, Crohn's disease, plaque psoriasis, acute coronary syndrome and complications during percutaneous coronary intervention. Despite blockbuster commercial success, integrins have remained out of reach as small molecule drugs...until now.
Morphic Therapeutic Address
35 Gatehouse Drive
Waltham, MA
United States
Morphic Therapeutic Email

Past Companies

Morphic TherapeuticGeneral Counsel, Corporate Secretary and Chief Compliance Officer
Evelo BiosciencesVice President, Intellectual Property
Cubist PharmaceuticalsDeputy Chief Intellectual Property Counsel

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.